Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota.

ABSTRACT: Toll-like receptor 2 (TLR2) expressed on myeloid cells mediates the recognition of harmful molecules belonging to invading pathogens or host damaged tissues, leading to inflammation. For this ability to activate immune responses, TLR2 has been considered a player in anti-cancer immunity. Therefore, TLR2 agonists have been used as adjuvants for anti-cancer immunotherapies. However, TLR2 is also expressed on neoplastic cells from different malignancies and promotes their proliferation through activation of the myeloid differentiation primary response protein 88 (MyD88)/nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB) pathway. Furthermore, its activation on regulatory immune cells may contribute to the generation of an immunosuppressive microenvironment and of the pre-met

SUBMITTER: Di Lorenzo A 

PROVIDER: S-EPMC7763461 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature